Iceni™ Pharmaceuticals Board of Directors


Board of Directors

Iceni Pharmaceuticals benefits greatly from an enthusiastic and dynamic team of professionals, backed up by an outstanding commercial, medical and regulatory expert advisory panel. Three of Iceni's team already have extensive first hand clinical development experience of cilengitide under a previous Merck Serono-sponsored glioblastoma treatment program.


John March, PhD

Chief Executive Officer

John has been involved in biotechnology commercialisation since 2007, when he set up BigDNA Ltd as an academic spin out. Since that time he has raised more than £4.3M of equity funding and was instrumental in licensing out BigDNA’s phage-based DNA vaccine technology to Eli Lilly animal health. Click for Bio


Christopher Hunt

Non-Executive Director

Christopher founded Fair-Lead Partners, a FCA regulated boutique advisory firm, in 2009 after a seventeen year career with blue chip Investment banks, predominantly in Asia. Click for Bio


Rhys Roberts, PhD

Non-Executive Director

Rhys brings more than 15 years’ experience in commercialisation of life science research in both academia and industry around the world, including previous roles with Origen Therapeutics and MerseyBIO, and he now advises a number of UK and international companies. Click for Bio

View our Commercial, Medical and Regulatory advisory board members, and learn about our expertise.